Core Viewpoint - The Hong Kong stock market is witnessing a significant surge in the innovative drug sector, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising over 110% since the beginning of the year, indicating a robust interest and investment in the biotech and healthcare industries [1] Group 1: Market Activity - 15 biopharmaceutical and healthcare companies have successfully listed on the Hong Kong Stock Exchange (HKEX) this year, raising a total of 189.93 billion HKD [2] - The leading innovative drug company, Hengrui Medicine, raised 98.9 billion HKD in its secondary listing, making it the top fundraiser in the Hong Kong pharmaceutical sector this year [2] - There is a notable disparity in fundraising amounts among newly listed companies, with 11 companies raising less than 10 million HKD, indicating a "head and tail" structure in the market [2] Group 2: Policy Support - The Hong Kong Stock Exchange has introduced new listing rules to facilitate the entry of biotech companies, significantly lowering the financing threshold for R&D-focused firms [3] - The Hong Kong Securities and Futures Commission has launched a "Special Technology Company Route" to streamline the listing process for innovative companies, reinforcing Hong Kong's position as a preferred listing platform [3] - Recent measures from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, including increased R&D support and inclusion in insurance directories [3] Group 3: International Expansion - The trend of Chinese innovative drug companies licensing out their products is gaining momentum, with a record potential milestone payment of approximately 12 billion USD from Hengrui Medicine's agreement with GSK [5] - The number of license-out transactions is expected to reach 94 in 2024, with a total transaction value of 519 billion USD, reflecting a 26% year-on-year increase [6] - The shift towards sustainable revenue generation through licensing agreements is anticipated to redefine the innovative drug sector in the Hong Kong market [6]

Group 1 - The core viewpoint of the article highlights the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and years [1] - The fund's latest net value is 2.0003 yuan, reflecting a growth of 1.17% [1] - Over the past month, the fund has achieved a return of 4.93%, ranking 412 out of 1032 in its category [1] - In the last six months, the fund's return has been 50.76%, ranking 43 out of 993 [1] - Year-to-date, the fund has returned 46.69%, ranking 69 out of 983 [1] Group 2 - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10%, with significant positions in companies such as Heng Rui Pharmaceutical (8.16%) and Zai Lab (7.99%) [1] - The fund was established on February 10, 2015, and as of June 30, 2025, it has a total size of 1.441 billion yuan [1] - The fund manager, Meng Yuan, has a master's degree and has held various positions in the financial industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1]

Core Viewpoint - Heng Rui Medicine has received acceptance notification from the National Medical Products Administration for its drug application of Haequibopam Ethanolamine Tablets, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [1] Group 1: Drug Development - The Phase III clinical trial (SHR8735-301) for Haequibopam Ethanolamine Tablets achieved its primary research endpoint as planned in May 2025 [1] - The study evaluated the efficacy and safety of Haequibopam Ethanolamine Tablets in patients with chemotherapy-induced thrombocytopenia through a multicenter, randomized, double-blind, placebo-controlled design [1] - A total of 213 adult patients with chemotherapy-induced thrombocytopenia were enrolled in the study, led by Professor Ma Jun from Harbin First Hospital and Professor Qin Shukui from Nanjing Tianyinshan Hospital [1] Group 2: Study Results - The results indicated that the treatment group significantly outperformed the control group on the primary efficacy endpoint [1] - The safety and tolerability of Haequibopam Ethanolamine Tablets were reported to be good [1]

Core Viewpoint - Heng Rui Medicine has received acceptance for its drug application for Haiqubopai Ethanolamine Tablets from the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [1][2] Group 1: Drug Approval and Clinical Trials - The National Medical Products Administration has issued an acceptance notice for the drug application of Haiqubopai Ethanolamine Tablets, which is indicated for adult patients with chemotherapy-induced thrombocytopenia [1] - The Phase III clinical trial (SHR8735-301) for Haiqubopai Ethanolamine Tablets achieved its primary endpoint in May 2025, demonstrating significant efficacy compared to the control group with good safety and tolerability [1] Group 2: Existing Approvals and Market Context - Haiqubopai Ethanolamine Tablets have previously been approved for two indications: chronic primary immune thrombocytopenia in adults with poor response to corticosteroids and immunoglobulins, and severe aplastic anemia in adults with poor response to immunosuppressive therapy [2] - The drug is an oral non-peptide thrombopoietin receptor (TPO-R) agonist that promotes platelet production through the activation of TPO-R mediated STAT and MAPK signaling pathways [2] - Similar products available in the international market include Eltrombopag, Avatrombopag, and Lusutrombopag, with a combined global sales forecast of approximately $2.59 billion for 2024 [2] - The cumulative R&D investment for Haiqubopai Ethanolamine Tablets has reached approximately 445.87 million yuan [2]

Group 1 - Company and its subsidiaries received approval from the National Medical Products Administration for clinical trials of HRS-4508 tablets, SHR-A1811 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - HRS-4508 is a novel, efficient, selective tyrosine kinase inhibitor that inhibits tumor cell proliferation [1] - The total R&D investment for HRS-4508 project is approximately 36.42 million yuan [1] Group 2 - SHR-A1811 injection binds to HER2-expressing tumor cells and induces apoptosis through a unique mechanism [2] - SHR-A1811 was approved for use in treating adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations [2] - The total R&D investment for SHR-A1811 project is approximately 1.26 billion yuan [2] Group 3 - Bevacizumab is a humanized anti-VEGF monoclonal antibody that has been approved in multiple countries since 2004 [3] - The global sales of Bevacizumab are projected to be approximately 5.655 billion USD in 2024 [3] - The total R&D investment for Bevacizumab injection project is approximately 3.45 million yuan [3]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of four new drugs, indicating a significant advancement in its oncology pipeline [1] Group 1: Drug Approvals - Heng Rui Medicine and its subsidiaries have been granted clinical trial approval for HRS-4508 tablets, SHR-A1811 injection, Adebeli monoclonal antibody injection, and Bevacizumab injection [1] - HRS-4508 is a novel, highly selective tyrosine kinase inhibitor that inhibits tumor cell proliferation to exert anti-tumor effects [1] - SHR-A1811 injection binds to HER2-expressing tumor cells, inducing apoptosis through a unique mechanism involving lysosomal release of toxins [1] Group 2: Immunotherapy Developments - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by Heng Rui Medicine, which reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [1] - Bevacizumab is a humanized anti-VEGF monoclonal antibody, further expanding the company's oncology treatment options [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) and its subsidiaries have received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating a significant advancement in their oncology pipeline [1] Group 1: Company Developments - The company, along with its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., has been granted clinical trial approval for HRS-4508, SHR-A1811, Adalimumab injection, and Bevacizumab injection [1] - The clinical trials will focus on HRS-4508 in combination with other anti-tumor treatments for solid tumors with abnormal HER2 pathways, specifically an open-label, multicenter Phase I/II study [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) and its subsidiaries have received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating a significant advancement in their oncology pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval notices for HRS-4508 tablets, SHR-A1811 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - The clinical trials will include an open-label, multicenter Phase I/II study of HRS-4508 in combination with other anti-tumor therapies for solid tumors with abnormal HER2 pathways [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-117 阿得贝利单抗注射液是公司自主研发的人源化抗 PD-L1 单克隆抗体，能通过 特异性结合 PD-L1 分子从而阻断导致肿瘤免疫耐受的 PD-1/PD-L1 通路，重新激 活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液 （商品名：艾瑞利）已于 2023 年 3 月获批上市，获批的适应症为与卡铂和依托 泊 苷 联 合 用 于 广 泛 期 小 细 胞 肺 癌 患 者 的 一 线 治 疗 。 国 外 有 同 类 产 品 Atezolizumab （ 商 品 名 ： Tecentriq ） 、 Avelumab( 商 品 名 ： Bavencio) 和 Durvalumab(商品名：Imfinzi)于美国获批上市销售，其中 Atezolizumab 和 Durvalumab 已在中国获批上市。国内有康宁杰瑞/思路迪药业的恩沃利单抗、基 石药业的舒格利单抗和正大天晴药业的贝莫苏拜单抗等同类产品获批上市。经查 询，2024 年 Atezolizumab、Avelumab 和 Durvalumab 全球销售额合计约为 96.48 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-118 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理的提示性公告 一、药品的基本情况 药品名称：海曲泊帕乙醇胺片 剂型：片剂 受理号：CXHS2500096 申报阶段：上市 申请人：江苏恒瑞医药股份有限公司 拟定适应症（或功能主治）：用于化疗为主的抗肿瘤治疗所致血小板减少症 成人患者。 二、药品的临床试验情况 2025 年 5 月，海曲泊帕乙醇胺片Ⅲ期临床试验（SHR8735-301）达到了方案 预设的主要研究终点。该研究是在化疗为主的抗肿瘤治疗所致血小板减少症患者 中评价海曲泊帕乙醇胺片有效性和安全性的多中心、随机、双盲、安慰剂对照的 Ⅲ期临床研究，由哈尔滨市第一医院马军教授和中国药科大学附属南京天印山医 院秦叔逵教授担任主要研究者，研究共入组 213 例化疗为主的抗肿瘤治疗所致血 小板减少症成人患者。研究结果表明，试验组在主要疗效终点上显著优于对照组， 且安全性和耐受性良好。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有 ...